Cargando…

Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy

BACKGROUND: to evaluate the role of a risk stratification system in intermediate-risk prostate cancer (PCa) treated with hypofractionated radiotherapy (HyRT). METHODS: 131 patients affected by intermediate-risk PCa were treated with HyRT at the total dose of 54,75 Gy in 15 fraction plus 9 months of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bracci, Stefano, Osti, Mattia F., Agolli, Linda, Bertaccini, Luca, De Sanctis, Vitaliana, Valeriani, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898326/ https://www.ncbi.nlm.nih.gov/pubmed/27276878 http://dx.doi.org/10.1186/s13014-016-0656-0

Ejemplares similares

Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy
por: Valeriani, Maurizio, et al.
Publicado: (2013)

Image guided intensity modulated hypofractionated radiotherapy in high-risk prostate cancer patients treated four or five times per week: analysis of toxicity and preliminary results
por: Valeriani, Maurizio, et al.
Publicado: (2014)

Image-Guided Hypofractionated Radiotherapy in Low-Risk Prostate Cancer Patients
por: Valeriani, Maurizio, et al.
Publicado: (2014)

Hypofractionated Radiotherapy in Intermediate-Risk Prostate Cancer Patients: Long-Term Results
por: Valeriani, Maurizio, et al.
Publicado: (2022)

Long term results of single high dose Stereotactic Body Radiotherapy in the treatment of primary lung tumors
por: Nicosia, Luca, et al.
Publicado: (2019)

Orbital Radiotherapy Plus Concomitant Steroids in Moderate-to-Severe Graves’ Ophthalmopathy: Good Results After Long-Term Follow-Up
por: Nicosia, Luca, et al.
Publicado: (2019)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?
por: De Sanctis, Vitaliana, et al.
Publicado: (2012)

Clinical Outcomes of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Patients with Lymph Node Metastases from Gynecological Cancers
por: Facondo, Giuseppe, et al.
Publicado: (2023)

Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience
por: Valeriani, Maurizio, et al.
Publicado: (2019)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Re-irradiation in lung disease by SBRT: a retrospective, single institutional study
por: Caivano, Donatella, et al.
Publicado: (2018)

Stereotactic body radiation therapy for the treatment of lymph node metastases: a retrospective mono-institutional study in a large cohort of patients
por: Caivano, Donatella, et al.
Publicado: (2023)

One-week vaginal brachytherapy schedule as exclusive adjuvant post-operative treatment in intermediate- and high-intermediate-risk endometrial cancer patients
por: De Sanctis, Vitaliana, et al.
Publicado: (2020)

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016)

Salvage radiotherapy with simultaneous integrated boost in non small-cell lung cancer patients with mediastinal relapse after surgery: a pilot study
por: Nicosia, L., et al.
Publicado: (2018)

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis
por: Chen, Jiuzhou, et al.
Publicado: (2023)

Ultra‐hypofractionated radiation therapy for unfavourable intermediate‐risk and high‐risk prostate cancer is safe and effective: 5‐year outcomes of a phase II trial
por: Macias, Victor A., et al.
Publicado: (2019)

Cytokines, Fatigue, and Cutaneous Erythema in Early Stage Breast Cancer Patients Receiving Adjuvant Radiation Therapy
por: De Sanctis, Vitaliana, et al.
Publicado: (2014)

Single nucleotide polymorphism of GSTP1 and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy
por: Nicosia, Luca, et al.
Publicado: (2018)

Integral Dose and Radiation-Induced Secondary Malignancies: Comparison between Stereotactic Body Radiation Therapy and Three-Dimensional Conformal Radiotherapy
por: D’Arienzo, Marco, et al.
Publicado: (2012)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Hypofractionated Radiotherapy in Localized, Low–Intermediate-Risk Prostate Cancer: Current and Future Prospectives
por: Lo Greco, Maria Chiara, et al.
Publicado: (2023)

Fractionated stereotactic radiosurgery for patients with skull base metastases from systemic cancer involving the anterior visual pathway
por: Minniti, Giuseppe, et al.
Publicado: (2014)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer
por: Soni, Abhishek, et al.
Publicado: (2022)

Patients’ Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer
por: De, Brian, et al.
Publicado: (2022)

Evolutionary process of Bos taurus cattle in favourable versus unfavourable environments and its implications for genetic selection
por: O'Neill, Christopher J, et al.
Publicado: (2010)

Archaeopedological analysis of colluvial deposits in favourable and unfavourable areas: reconstruction of land use dynamics in SW Germany
por: Henkner, Jessica, et al.
Publicado: (2018)

Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer
por: He, Jiaoxue, et al.
Publicado: (2023)

Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer
por: Reverberi, C., et al.
Publicado: (2020)

Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study
por: Facondo, Giuseppe, et al.
Publicado: (2023)

Review of Hypofractionated Radiotherapy for Prostate Cancer
por: Spyropoulou, Despina, et al.
Publicado: (2012)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Impact of Androgen Deprivation Therapy Associated to Conformal Radiotherapy in the Treatment of D’Amico Intermediate-/High-Risk Prostate Cancer in Older Patients
por: Couderc, Anne-Laure, et al.
Publicado: (2020)

Investigating the Benefit of Combined Androgen Modulation and Hypofractionation in Prostate Cancer
por: Zamagni, Alice, et al.
Publicado: (2020)

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?
por: Eom, Keun-Yong, et al.
Publicado: (2014)

Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy
por: Erlandsson, Ann, et al.
Publicado: (2023)

Hypofractionated External-Beam Radiotherapy for Prostate Cancer
por: Cho, L. Chinsoo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_619l47k433jju3i30j2vt3bbam